Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979635 | 0.82 | CYP4F2 (0.51) | HTTKDM4EHSD17B10TP53GAA | |
| SCHEMBL24202214 | 0.81 | HTT (0.45) | HTTKDM4EHSD17B10TP53GAA | |
| SCHEMBL7658347 | 0.81 | TOP1 (0.47) | HTTKDM4EHSD17B10GAAMAPT | |
| SCHEMBL19640145 | 0.80 | HTT (0.37) | HTTKDM4EHSD17B10TP53GAA | |
| SCHEMBL7659166 | 0.79 | TUBB4A (0.50) | HSD17B10GAAMAPTALDH1A1ALOX5 | |
| SCHEMBL8673567 | 0.79 | HTT (0.44) | HTTKDM4EHSD17B10TP53GAA | |
| SCHEMBL15463122 | 0.79 | HTT (0.44) | HTTKDM4EHSD17B10TP53GAA | |
| SCHEMBL28717635 | 0.79 | THRB (0.45) | HTTKDM4EHSD17B10TP53GAA | |
| SCHEMBL12445342 | 0.78 | ALDH1A1 (0.44) | HTTKDM4EHSD17B10TP53GAA | |
| SCHEMBL5034651 | 0.78 | HMGB1 (0.51) | HTTKDM4EHSD17B10TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536336-B2 | Prodrug compounds useful as cannabinoid ligands | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2011075522-A1 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144165-A1 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | US | disclosed |
| EP-1468692-B1 | Use of 2,6-di-alkyl-4-silyl-phenols for treating xanthoma | MERRELL PHARMA INC (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-0732928-B1 | METHOD OF LOWERING SERUM CHOLESTEROL LEVELS WITH 2,6-DI-ALKYL-4-SILYL-PHENOLS | MERRELL PHARMA INC (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1468692-A2 | Use of 2,6-di-alkyl-4-silyl-phenols for treating xanthoma | MERRELL PHARMACEUTICALS INC. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1468693-A2 | Use of 2,6-di -alkyl-4-silyl-phenols for treating diabetes mellitus | MERRELL PHARMACEUTICALS INC. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-0942896-B1 | SUBSTITUTED PHENOLS AND THIOPHENOLS USEFUL AS ANTIOXIDANT AGENTS | AVENTIS PHARMA INC (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-0998477-B1 | Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents | AVENTIS PHARMA INC (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-0900225-B1 | ALKYL-4-SILYL-PHENOLS AND ESTERS THEREOF AS ANTIATHEROSCLEROTIC AGENTS | AVENTIS PHARMA INC (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-0732928-A1 | METHOD OF LOWERING SERUM CHOLESTEROL LEVELS WITH 2,6-DI-ALKYL-4-SILYL-PHENOLS | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5532400-A | 2,6-di-alkyl-4-silyl-phenols as antiatheroscelerotic agents | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0464852-B1 | Novel 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents and as antioxidants | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0464844-B1 | Novel bis (4-(2,6-di-alkyl)phenol)silane derivatives as antiatherosclerotic agents and as antioxidants | MERRELL DOW PHARMA (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1995015760-A1 | METHOD OF LOWERING SERUM CHOLESTEROL LEVELS WITH 2,6-DI-ALKYL-4-SILYL-PHENOLS | MERRELL PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | disclosed |
| US-5304668-A | Bis-[4-(2,6-di-alkyl)phenolisilane derivatives as antiatherosclerotic agents | MERRELL DOW PHARMACEUTICALS (US) | 1994-04-19 | — | — | US | disclosed |
| US-5281738-A | Anticholesterol agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-01-25 | — | — | US | disclosed |
| US-5155250-A | 2,6-DI-ALKYL-4-SILYL-PHENOLS AS ANTIATHEROSCEROTIC AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0464844-A1 | Novel bis (4-(2,6-di-alkyl)phenol)silane derivatives as antiatherosclerotic agents and as antioxidants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464852-A1 | Novel 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents and as antioxidants | MERRELL PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144165-A1 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS | CNR2, CNR1, OPRL1 | HTT 3988/4885KDM4E 2269/4885HSD17B10 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.